North America Drug Screening Market

North America Drug Screening Market Size (2023 to 2028)

The size of the Drug Screening Market in North America was worth USD 2.64 billion in 2023. It is expected to grow at a CAGR of 10.2% to approach USD 4.29 billion by 2028.

Drug screening, otherwise known as drug testing, is performed in various cases, such as when patients are unconscious and cannot tell what drug they have taken earlier. Drug tests are also done for patients to identify which drugs they are allergic to and in cases of known drug allergic conditions with pain management. The testing process involves collecting various samples, including skin, hair follicles, blood, saliva, and urine. Various factors, including increased population, increased medicine, healthcare, infrastructure, rise in chronic diseases, and rise in intake of drugs by patients, contribute to the growth of the drug screening market. The increase in patients who are allergic to some compositions of drugs also increases market size. For various religious reasons, the ban on substances and drugs is seen. In such cases, the drug screening process is performed in terms of substance abuse. People in this region are more aware of drug screening policy increases market size. Growing demand for safety rules and regulations in every place and increasing drug, alcohol, and substance abuse are significant growth driving factors for the drug screening market in developed countries. Government initiatives for a ban on drugs of abuse and an increase in fundraising activities and awareness of healthy lifestyle activities positively impact the market and increase the market growth.

Besides growth contributing factors, few market restraints held back market growth. Factor such as the availability of masking agents in order to mask drug screening tests is a significant concern for drug screening tests. In some parts of this region, drug testing is considered a violation and against privacy rights. Also, there are a lot of accuracy issues with devices used for drug screening or testing. Devices such as breath analyzers, sample collection devices need to be available at the right time, and the functioning of these devices is to be checked properly in order to avoid errors in testing.

COVID-19 Impact:

During COVID 19, there are many travel ban issues and lockdown regulations to prevent the spread of the virus. There is a lack of skilled workers and staff for various clinics, hospitals, and diagnostic centers. Hence this affected market in a huge scenario. The people who wanted to get drug-screened or tested could not get in touch with healthcare workers as they got indulged in COVID healthcare schemes and regulations. A negative impact on the medical tourism market in turn impacted on drug screening market.

This research report on the North America drug screening market has been segmented and sub-segmented into the following categories:

• By Sample Type: Hair, Blood, Urine, and Others
• By End-user: Hospitals, Workplaces, Criminal Justice and Law Enforcement
• By Products And Services: Breathalyser, Rapid Test Device, Immunoassay Analyser, Chromatography, and Others
• By Country: The United States, Canada, and Rest of North America

Regional Analysis:

Based on the market performances, the North American market is calculated to continue growing at a very high growth rate in the recent future. It is forecast that the region will remain the top market share provider to the global market till the end of 2025, because of the strict enacting of rules and regulations by the governmental law enforcement agencies in the region.

North America is a highly populated region with well-developed healthcare and infrastructure, advanced technology, and research & activities. These states have high hospitality facilities and patients consuming drugs for various chronic diseases. The United States and Canada consist of maximum patients, and hence drug intake is also in high amount in total. Also, these states carry out high weightage with pharmaceutical, nutraceuticals. The United States carries out extensive primary research with healthy volunteers.

Companies playing a dominant role in the North America Drug Screening Market profiled in this report are Thermo Fisher Scientific Inc., Express Diagnostics Int’l Inc., Abbott Laboratories, Siemens AG, Alere Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Biorad Laboratories Inc., Shimadzu and Omega Laboratories.